Jul. 24 at 3:31 PM
$ESTA
7/15/25 Mizuho
Anthony Petrone
Flash update only
- Establishment Labs (ESTA, Outperform): US Motiva now firmly in the upswing on its S-curve.
Our recent channel checks with two of the largest breast implant surgeons in the country show Motiva is on the way to commanding 25% of practice share across US board-certified plastic surgeons.
Share is being driven by patient preference for: 1) demand for a smaller cup size/natural look post-intervention, 2) increasing real world evidence of 0% capsular contracture, 3) best-in-class safety profile of 0% breast implant-associated anaplastic large cell lymphoma (BIA-ALCL).
Looking ahead, we see upside to the
$35MN+ full-year guidance estimate for 2025 as well as our peak penetration target over the next three years
